Concurrent Chemoradiation and Durvalumab for Locoregionally Advanced Nasopharyngeal Carcinoma
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
The investigators propose a phase II randomized-controlled study on using durvalumab in
combination with induction chemotherapy followed by concurrent chemoradiation and adjuvant
durvalumab, compared to induction chemotherapy followed by concurrent chemoradiation for
previously untreated locoregionally advanced stage III to IVA NPC. In parallel, the
investigators will also perform collateral tumor and serum biomarker studies which will be
correlated with the treatment response. The investigators will collect fresh tumour biopsies
at pretreatment, then serially after induction chemotherapy and after concurrent
chemoradiation to investigate the change in microenvironment of the tumour and the
surrounding inflammatory cells before and after durvalumab. In addition, the investigators
will also measure the change in number and intensity of PD-L1-positive circulating tumour
cells (CTC) before and after durvalumab and evaluate their correlation with treatment
response.